聚合酶链反应用于肝硬变门静脉高压症病原学研究

Polymerase chain reaction used for the e-tiologic research with liver cirrhosis portal hypertension

应用聚合酶链反应（ＰＣＲ）及酶联免疫吸附试验（ＥＬＩＳＡ）检查发现：肝硬变门静脉高压症处于乙型肝炎病毒（ＨＢＶ）、丙型肝炎病毒（ＨＣＶ）感染状态的比率分别为８０．７％及３７．８％；处于ＨＢＶ、ＨＣＶ活跃复制状态的比率分别为３１．６％及２９．８％。ＨＢＶ，ＨＣＶ感染指标至少有一项阳性的比率为８６．７％，手术治疗组及内科治疗组病人的乙型肝炎血清标志及丙型肝炎感染状态比较均无显著性差异（Ｐ＞０．０５）。ＨＣＶＲＮＡ及ＨＢＶＤＮＡ阳性病人的输血史比率分别为８２．４％及４７．１％，差异有显著意义（Ｐ＜０．０５）。说明肝硬变门静脉高压症病人只对症治疗是不够的，应行积极的抗病毒治疗；有输血史的该症病人应检查ＨＢＶＤＮＡ及ＨＣＶＲＮＡ，以便早发现输血后肝炎（ＰＴＨ）。

The continuous aboundant duplication ofhepatitis virus is the main cause of reductionin liver function resulting to liver cirrhosisportal hypertension.It was discovered by theuse of polymerase chain reaction(PCR) andELISA that the ratio of infeceive state of hep-atitis B virus(HBV)and hepatitis C virus(HCV) were 80.7%and 37.8%respectively.The active duplicating state ratio of HBV andHCV was also determined to be 31.6%and29.8%respectively.The ratio of at least oneinfective index in HBV and HCV to be positivewas86.7%.Serum HBV markers and HCVinfective state of patients who received surgi-cal therapy compared to those who receiveddrug therapy showed no significant differences(P>0.05).The ratio of patients with bolldtrancfusion history in HCV RNA and HBVDNA positive patients were 82.4%and47.1%respectively,with significant differ-ences(P<0.05).It could therefore be seenfrom the above data that using only symp-tomatic treatment of liver corrhosis portal hy-pertension is inadpquate and therefore requiresactive anti-virus treatment.Liver cirrhosisportal hypertensive patients with blood trans-fusion history should be given early check forHBV DNA and HCV RNA to facilitate earlydiscovery of post-transfusion hepatitis(PTH).